CONFLICT OF INTEREST STATEMENT C.B. has received consulting or speaking honoraria from Embecta, Insulet, Medtronic and Tandem. S.F.A. participated in a 2022 advisory discussion for Dexcom for which she was not financially compensated. Prior to 2019, she received speaker fees, funding to attend meetings and/or honoraria from Dexcom, Eli Lilly, Novo Nordisk and Sanofi.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Torben Biester
International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Diabetes Technologies - Insulin Delivery
Keywords Humans, Adolescent, Child, Insulin, Insulin Infusion Systems, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Societies, Medical, Male, Female, Consensus, Young Adult, Pump, Automated insulin delivery, Children, Diabetes Abstract The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide.
Nutrients | Free Full-Text | Alterations in Dietary Behavior, Appetite Regulation, and Health-Related Quality of Life in Youth with Obesity in Germany during the COVID-19 Pandemic
1. Introduction Adolescence is a critical period characterized by rapid growth, physical development, and significant changes in dietary patterns. Proper nutrition during this period is essential to support optimal growth, development, and overall health. However, adolescents often face unique challenges in achieving a healthy diet due to various factors, such as increased autonomy in food choices, exposure to unhealthy food environments, and peer influences.
Long-term Occupational Consequences for Families of Children With Type 1 Diabetes: The Mothers Take the Burden
Clinical Care/Education/Nutrition/Psychosocial Research Abstract OBJECTIVE To investigate the occupational and financial consequences for parents following the onset of type 1 diabetes in their child.
The Automated Pancreas: A review of technologies and clinical practice
SUPPLEMENTARY ARTICLE Torben Biester MD, Corresponding Author AUF DER BULT biester@hka.de orcid.org/0000-0001-8051-5562 Diabetes Center for Children and Adolescents, Janusz-Korczak-Allee 12, Hannover, Germany Corresponding Author: Torben Biester ( biester@hka.de)Search for more papers by this author Dr. Martin Tauschmann PhD, Department of Pediatric and Adolescent Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, Austria Search for more papers by this author Agata Chobot...
Add‐on Therapy with Dapagliflozin under Full Closed Loop Control improves Time in Range in Adolescents and young Adults with Type 1 Diabetes- The DAPADream Study - Biester - - Diabetes, Obesity and Metabolism - Wiley Online Library
ORIGINAL ARTICLE Torben Biester Corresponding Author biester@hka.de orcid.org/https://orcid.org/0000-0001-8051-5562 Diabetes Centre for Children and Adolescents, Kinder‐ und Jugendkrankenhaus Auf der Bult, Hannover, Germany Correspondence Dr. Torben Biester Children's Hospital AUF DER BULT Janusz‐Korczak‐Allee 12 30173 Hannover +49 511 8115 3344 +49 511 8115 993344 Email: biester@hka.de Search for more papers by this author Moshe Phillip The Jesse Z.
DREAM5: An open‐label, randomized, cross‐over study to evaluate the safety and efficacy of day and night closed‐loop control by comparing the MD‐Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at h
Abstract Aims Previous DREAM studies demonstrated the safety and efficacy of the CE marked MD‐Logic closed‐loop system (DreaMed GlucoSitter) in different settings for overnight glycaemic control. The present study aimed to evaluate the system for day and night use for 60 hours during the weekend at home compared to sensor‐augmented pump (SAP) therapy in participants with type 1 diabetes. Methods This was a prospective, multicentre, crossover, controlled study (clinicaltrials.gov NCT01238406).
DREAM5: An open‐label, randomized, cross‐over study to evaluate the safety and efficacy of day and night closed‐loop control using the MD‐Logic automated insulin delivery system compared to sensor augmented pump therapy in patients with type 1 diabetes at
Aims Previous DREAM studies demonstrated the safety and efficacy of the CE marked MD‐Logic closed‐loop system (DreaMed GlucoSitter™) in different settings for overnight glycaemic control. The present study aims to evaluate the system for day and night use for 60 hours during weekend time at home compared to sensor‐augmented pump (SAP) therapy in participants with type 1 diabetes. Methods This was a prospective, multicenter, crossover, controlled study.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Torben
Contact Torben, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack